A randomized trial shows dose-frequency and genotype may determine the therapeutic efficacy of intranasal oxytocin
BackgroundThe neuropeptide oxytocin is proposed as a promising therapy for social
dysfunction by modulating amygdala-mediated social-emotional behavior. Although clinical …
dysfunction by modulating amygdala-mediated social-emotional behavior. Although clinical …
[PDF][PDF] A randomized trial shows dose-frequency and genotype may determine the therapeutic efficacy of intranasal oxytocin 2
J Kou, Y Zhang, F Zhou, C Sindermann - scholar.archive.org
Background. The neuropeptide oxytocin is proposed as a promising therapy for social 24
dysfunction by modulating amygdala-mediated social-emotional behavior. Although 25 …
dysfunction by modulating amygdala-mediated social-emotional behavior. Although 25 …
A randomized trial shows dose-frequency and genotype may determine the therapeutic efficacy of intranasal oxytocin.
J Kou, Y Zhang, F Zhou, C Sindermann… - Psychological …, 2020 - europepmc.org
Background The neuropeptide oxytocin is proposed as a promising therapy for social
dysfunction by modulating amygdala-mediated social-emotional behavior. Although clinical …
dysfunction by modulating amygdala-mediated social-emotional behavior. Although clinical …
A randomized trial shows dose-frequency and genotype may determine the therapeutic efficacy of intranasal oxytocin
J Kou, Y Zhang, F Zhou, C Sindermann, C Montag… - medRxiv, 2020 - medrxiv.org
Background The neuropeptide oxytocin is proposed as a promising therapy for social
dysfunction by modulating amygdala-mediated social-emotional behavior. Although clinical …
dysfunction by modulating amygdala-mediated social-emotional behavior. Although clinical …
A randomized trial shows dose-frequency and genotype may determine the therapeutic efficacy of intranasal oxytocin
J Kou, Y Zhang, F Zhou, C Sindermann… - Psychological …, 2022 - search.proquest.com
Background The neuropeptide oxytocin is proposed as a promising therapy for social
dysfunction by modulating amygdala-mediated social-emotional behavior. Although clinical …
dysfunction by modulating amygdala-mediated social-emotional behavior. Although clinical …
A randomized trial shows dose-frequency and genotype may determine the therapeutic efficacy of intranasal oxytocin
J Kou, Y Zhang, F Zhou, C Sindermann… - Psychological …, 2022 - hub.hku.hk
Background The neuropeptide oxytocin is proposed as a promising therapy for social
dysfunction by modulating amygdala-mediated social-emotional behavior. Although clinical …
dysfunction by modulating amygdala-mediated social-emotional behavior. Although clinical …
A randomized trial shows dose-frequency and genotype may determine the therapeutic efficacy of intranasal oxytocin
J Kou, Y Zhang, F Zhou, C Sindermann, C Montag… - 2022 - pubmed.ncbi.nlm.nih.gov
Background The neuropeptide oxytocin is proposed as a promising therapy for social
dysfunction by modulating amygdala-mediated social-emotional behavior. Although clinical …
dysfunction by modulating amygdala-mediated social-emotional behavior. Although clinical …
A randomized trial shows dose-frequency and genotype may determine the therapeutic efficacy of intranasal oxytocin
J Kou, Y Zhang, F Zhou, C Sindermann, C Montag… - 2020 - europepmc.org
Background The neuropeptide oxytocin is proposed as a promising therapy for social
dysfunction by modulating amygdala-mediated social-emotional behavior. Although clinical …
dysfunction by modulating amygdala-mediated social-emotional behavior. Although clinical …